mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for CSNK1G3
Gene summary
Basic gene Info.Gene symbolCSNK1G3
Gene namecasein kinase 1, gamma 3
SynonymsCKI-gamma 3|CSNK1G3L
CytomapUCSC genome browser: 5q23
Type of geneprotein-coding
RefGenesNM_001031812.3,
NM_001044723.2,NM_001270572.1,NM_001270573.1,NM_001270574.1,
NM_004384.4,NM_001044722.1,
Descriptioncasein kinase I isoform gamma-3
Modification date20141207
dbXrefs MIM : 604253
HGNC : HGNC
Ensembl : ENSG00000151292
HPRD : 05034
Vega : OTTHUMG00000128923
ProteinUniProt: Q9Y6M4
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_CSNK1G3
BioGPS: 1456
PathwayNCI Pathway Interaction Database: CSNK1G3
KEGG: CSNK1G3
REACTOME: CSNK1G3
Pathway Commons: CSNK1G3
ContextiHOP: CSNK1G3
ligand binding site mutation search in PubMed: CSNK1G3
UCL Cancer Institute: CSNK1G3
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID


Top
Ligand binding site mutations for CSNK1G3

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
E166E166DCOAD1
E86E86KCOAD1
P100G98VLUAD1
N53G52CLUAD1
T271P272QSKCM1
D185D185YSTAD1
P18S19GTHCA1
N53G52DUCEC1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for CSNK1G3
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
P100G98V0.11314872
E86E86K-1.2856404
E166E166D-1.1426993
D185D185Y-0.78128063
T271P272Q-0.54149376
P18S19G-0.37192129
N53G52D-0.35338084
N53G52C-0.15281246
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for CSNK1G3 from PDB

Top
Differential gene expression and gene-gene network for CSNK1G3
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of CSNK1G3 and the right PPI network was created from samples without mutations in the LBS of CSNK1G3. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for CSNK1G3
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for CSNK1G3
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
ExperimentalDB04751Purvalanol ASmall molecule
ExperimentalDB07488{(2Z)-4-AMINO-2-[(4-METHOXYPHENYL)IMINO]-2,3-DIHYDRO-1,3-THIAZOL-5-YL}(4-METHOXYPHENYL)METHANONESmall molecule
ExperimentalDB07489{[4-AMINO-2-(3-CHLOROANILINO)-1,3-THIAZOL-5-YL](4-FLUOROPHENYL)METHANONESmall molecule
ExperimentalDB076645-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDESmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of CSNK1G3 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
MGMAGNESIUM(2+)2izsAD185
DKICDK1/2 INHIBITOR III2chlAE166 D185
0YO2-[5-METHOXY-2-(QUINOLIN-3-YL)PYRIMIDIN-4-YL]-1,5,6,7- TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE4hglAE86 P100 D185
BRK{(2Z)-4-AMINO-2-[(4-METHOXYPHENYL)IMINO]-2,3-DIHYDRO-1,3-THIAZOL-5-YL}(4-METHOXYPHENYL)METHANONE2izrAN53
BRQ{[4-AMINO-2-(3-CHLOROANILINO)-1,3-THIAZOL-5-YL](4-FLUOROPHENYL)METHANONE2izsAN53
15G2-{2-[(3,4-DIFLUOROPHENOXY)METHYL]-5-METHOXYPYRIDIN-4- YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE4hgsAP100 D185
P01PURVALANOL A2izuAP100 E166


Top
Conservation information for LBS of CSNK1G3
Multiple alignments for Q9Y6M4 in multiple species
LBSAA sequence# speciesSpecies
A70TNEYVAIKLEP4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
D125GPSLEDLFDLC4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
D162NLIYRDVKPEN4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
D185VIHIIDFGLAK4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
E117NAMVLELLGPS4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
E166RDVKPENFLIG4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
E86PQLHLEYRFYK4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
F54IGCGNFGELRL4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
G120VLELLGPSLED4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
G50VGKKIGCGNFG4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
I184QVIHIIDFGLA4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
I49RVGKKIGCGNF4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
K164IYRDVKPENFL4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
K72EYVAIKLEPMK4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
L116YNAMVLELLGP4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
L118AMVLELLGPSL4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
L119MVLELLGPSLE4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
L169KPENFLIGRPG4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
L57GNFGELRLGKN4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
N167DVKPENFLIGR4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
N53KIGCGNFGELR4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
P100SGDGIPQVYYF4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
P121LELLGPSLEDL4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
P18DRMARPSGRSG3Homo sapiens, Mus musculus, Rattus norvegicus
P18--MARPSGRLG1Bos taurus
P331IGKQLPTPVGA3Homo sapiens, Mus musculus, Rattus norvegicus
P331-----------1Bos taurus
P333KQLPTPVGAVQ3Homo sapiens, Mus musculus, Rattus norvegicus
P333-----------1Bos taurus
T271DTKRATPIEVL4Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus
T332GKQLPTPVGAV3Homo sapiens, Mus musculus, Rattus norvegicus
T332-----------1Bos taurus


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas